Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
138.99
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?
March 11, 2022
Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.
Via
InvestorPlace
What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today
March 11, 2022
Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM...
Via
Benzinga
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
March 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In...
Via
Benzinga
Chinese Stocks Are Falling: What's Going On?
March 10, 2022
Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as...
Via
Benzinga
BeiGene: Q4 Earnings Insights
February 25, 2022
BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
CStone's Commercialization Capacity Put to Test With Latest Drug Approval
February 14, 2022
Key takeaways:
Via
Benzinga
Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble
March 10, 2022
The SEC is calling out a several stocks for non-compliance. Could they face delisting?
Via
Investor's Business Daily
Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses
March 08, 2022
Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D...
Via
Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Via
Benzinga
BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia
February 22, 2022
The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for...
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
January 26, 2022
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept...
Via
Benzinga
Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies
January 25, 2022
Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own...
Via
Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...
Via
Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...
Via
Benzinga
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
January 19, 2022
Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric...
Via
Benzinga
Death Cross Looms Over BeiGene Investors
January 03, 2022
If history is any guide, there may be trouble ahead for shares of BeiGene (NASDAQ:BGNE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
December 26, 2021
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis...
Via
Talk Markets
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
December 22, 2021
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders.
Via
InvestorPlace
Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B
December 20, 2021
BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and...
Via
Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
December 18, 2021
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.
Via
Talk Markets
46 Biggest Movers From Yesterday
December 16, 2021
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
December 15, 2021
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
December 15, 2021
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
December 15, 2021
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target....
Via
Benzinga
BeiGene Unveils Results From Late-Stage Tislelizumab In Nasopharyngeal Cancer
December 10, 2021
BeiGene Ltd (NASDAQ: BGNE) revealed the detailed data from the Phase 3 RATIONALE 309 trial of tislelizumab for nasopharyngeal cancer. The trial evaluated...
Via
Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...
Via
Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
December 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
December 04, 2021
Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. It is the third listing for the company,...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.